Table 5

Antitumor activity of ZD1839, taxanes, and GEM given alone or in combination against human lung tumors xenografted to nude mice

Two to three experiments of three to four mice/group.

TumorDrug compoundaAverage weight change (%)Average tumor diameterb,c (mm ± SE)Change in tumor volumeb,c (mm3)Tumor-free mice (no./total)
LX-1−415.2 ± 2+18050 /9
ZD1839 (50)−612.5 ± 3+9810 /9
PTXL (25)−36.3 ± 1+890 /9
DTXT (20)−47.4 ± 2+1620 /9
ZD1839+ PTXL−52.8 ± 1−513 /9d
ZD1839 + DTXT−65.6 ± 1+420 /9
A549+112.2 ± 2+9070 /8
ZD1839 (50)−39.6 ± 1+8090 /8
PTXL (25)−24.4 ± 1−90 /8
DTXT (20)−14.3 ± 1−80 /8
GEM (350)−35.2 ± 2+310 /8
ZD1839+ PTXL−42.4 ± 1−522 /8d
ZD1839+ DTXT−32.5 ± 1−551 /8d
ZD1839+ GEM−55.3 ± 1+350 /8
  • a ZD1839 given (qd × 5) × 2 and cytotoxics given every 3–4 days × 4 at 3–4 day after transplant.

  • b Initial tumor mass was 55–63 mg (4.9 ± 0.1 mm diameter).

  • c Measurements made 2–3 days after dose or at the nadir for a regressing tumor.

  • d Tumor regrowth in two of three (LX-1), one of two (A549) and one of one mice 21 days after treatment.